FiercePharma

Gilead's Descovy snared its PrEP data, but can it stand up to Truvada generics?

Gilead Sciences has the data it’ll need to start transitioning patients taking Truvada for PrEP over to Descovy, a drug with a longer patient life. But once Truvada generics hit, it might be a ...
FiercePharma

Gilead's converting Truvada PrEP users to Descovy faster than expected: analyst

One big task for Gilead Sciences’ HIV franchise in the coming year is to save some $2.5 billion in annual sales by switching as many PrEP patients as possible from Truvada to newly approved Descovy ...
Monthly Prescribing Reference

Descovy for PrEP Continues to Be Noninferior to Truvada, According to 96 Week Data

Descovy demonstrated continued noninferiority to Truvada for HIV pre-exposure prophylaxis and statistically significant differences over Truvada for pre-specified secondary end points. In the phase 3, ...
Nasdaq

Gilead Presents New Findings on Profile of Descovy® for Potential Use as HIV Pre-exposure Prophylaxis Compared With Truvada®

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (NASDAQ: GILD) today presented additional results from the DISCOVER trial evaluating an investigational use of Descovy (emtricitabine 200 ...
Yahoo

FDA Approves Second Drug To Be Used As PrEP: Descovy

Add Yahoo as a preferred source to see more of our stories on Google. Today, the U.S. Food and Drug Administration approved Gilead’s drug Descovy to be used as PrEP, an HIV prevention strategy that ...